Novartis Articles
Novartis finally reaches agreement with Alcon’s minority shareholders for full control
15 December 2010
EMA advised Pfizer is withdrawing Thelin due to serious liver damage; starts somatropin drugs review
13 December 2010
US Supreme Court agrees to hear generic drug labelling case; Teva files to stop generic Copaxone
13 December 2010
Aromatase inhibitors may increase risk of heart disease in postmenopausal women with breast cancer
10 December 2010
Novartis’ Zometa fails to meet Ph III primary endpoint in early breast cancer, stalling this indication; but Afinitor looks good
10 December 2010
ASH meeting: Pfizer’s bosutinib disappoints in myeloid leukemia trial; Novartis’ Tasigna beats Glivec in CML study
7 December 2010
Attitudes of US relapsing-remitting multiple sclerosis patients to current and emerging therapies
6 December 2010
Novartis US unit restructures, slashing 1,400 pharma field staff; to showcase oncology drugs at ASH meeting
1 December 2010
UK’s NICE not to recommend Roche’s Tarceva for NSCLC and Novartis’ Afinitor rejected for kidney cancer, with both drugmakers to appeal
26 November 2010
Roche convinces UK’s NICE to recommend Herceptin for metastatic gastric cancer; Novartis fail in higher dose Glivec
25 November 2010
Ph III studies show Bayer and Regeneron VEGF Trap-Eye in wet AMD meets primary endpoints versus Lucentis
22 November 2010
Novartis unveils group-wide productivity initiatives to improve efficiency in manufacturing, sales, marketing and procurement
18 November 2010
Aires Pharma signs option deal with Novartis based on Aironite worth up to $250 million; raises $20 million
12 November 2010
Novartis takes $120 million charge as it drops vadimezan development
11 November 2010
Novartis’ Onbrez Breezhaler beats Spiriva in new study of COPD patients; Afinitor reduces SEGAs size
4 November 2010
US FDA approves Novartis Afinitor for SEGA, Forest’s Teflaro for CABP and Avanir’s Nuedexta for PBA
1 November 2010
Novartis to invest $600 million to expand its global research headquarters in the USA
28 October 2010
Negative decisions from UK’s NICE for Novartis’ Xolair, GSK’s Arzerra and Pfizer’s Torisel, but OK for Amgen’s Prolia
27 October 2010
Positive vaccine trial results from Novartis, Sanofi Pasteur and LigoCyte presented at IDSA meeting
26 October 2010
Novartis and Merck & Co present strong data on Fluad and Zostavax, respectively, at IDSA meeting
22 October 2010
US FDA clears Mylan’s generic versions of Hyzaar and Cozaar and Watson’s copy of Lotrel; Watson settles with Endo
18 October 2010
Novartis once-yearly Reclast preserves bone mass, provides fracture protection in postmenopausal osteoporosis, long term data show
18 October 2010
USA’s FDA calls for label changes on bisphosphonates due to possible increased risk of thigh bone fracture
14 October 2010
ImmunoGen collaborates with Novartis on cancer drugs for $45 million upfront, plus potential $200 million per target; updates financials
12 October 2010
UK’s NICE does about turn on Alzheimer’s drugs but unable to recommend Merck & Co/J&J’s psoriatic arthritis drug Simponi
7 October 2010
Novartis drops development of albinterferon and Mycograb in candidiases, taking $590 million charge
6 October 2010
Roche hires new head of inflammation/virology research; Hospira recruits former Actavis exec; Alcon names new CFO
5 October 2010
Bisphosphonates under scrutiny in Europe over link to stress fractures
28 September 2010
Novartis sells US rights to the overactive bladder drug Enablex to Warner Chilcott for $400 million plus
26 September 2010
Positive CHMP opinions for AstraZeneca and Novartis, but suspension of Octapharma’s Octagam called for; Roche Avastin review
26 September 2010
US FDA approves Bayer’s Beyaz, a combination contraceptive with folate, and Allergan’s Ozurdex
26 September 2010
Alnylam to cut work force by up to 30% as five-year deal with Novartis comes to a close
26 September 2010
Nomura ups sales forecast for Novartis’s new oral MS drug Gilenya to $3.5 billion, as Biogen Idec says it is still confident about non oral products
24 September 2010
Novartis gains FDA approval for Gilenya, first oral MS drug cleared in USA; says SOM230 effective against Cushing’s disease
22 September 2010
Novartis pulls European marketing authorization application for aliskiren and valsartan combo Rasival; presents new data on Onbrez Breezhaler
20 September 2010
UK’s NICE calls for more data on Bristol-Myers/Otsuka’s Abilify for schizophrenia; Scotland backs Novartis’Glivec
14 September 2010
Novartis gets Russian approval for oral MS drug Gilenya (fimgolimid)
13 September 2010
Idenix Pharma slumps as US FDA puts “clinical hold” on two of the firm’s hepatitis C programs
8 September 2010
Silence Thera receives takeover approach from unnamed drug firm
7 September 2010
Bausch & Lomb moves to acquire Miochol-E from Novartis as required by US competition authority
7 September 2010
Regulatory briefs: Shire’s Vpriv cleared in Europe; Menactra for toddlers; Updates for Novartis and Roche
27 August 2010
UK’s NICE gives final “no” to NHS use of Novartis cancer drug Glivec; Novartis now holds 77% of Alcon
26 August 2010
US FDA questions safety of Novartis/Orion’s Stalevo due to possible increased cardiovascular risk
23 August 2010
Quark Pharma in option deal with Novartis that could earn it $670 million for siRNA drug QPI-1002; planning IPO
19 August 2010
Novartis buy of Alcon moves forward, but USA and China competition authorities call for divestments
17 August 2010
UK’s NICE reaffirms decision to deny use of Novartis’ asthma drug Xolair for children
13 August 2010
UK sees launch of Novartis COPD drug Onbrez Breezhaler, which Scotland clears for NHS use
11 August 2010
US FDA approves first generic of Sanofi-Aventis’ Lovenox for Sandoz, for DVT prevention
26 July 2010
Eight novel disease-modifying therapies will drive modest growth in the multiple sclerosis drug market through 2019
13 July 2010
Novartis must get Alcon IDC approval for buyout, says Swiss corporate governance expert
29 June 2010
Novartis gets US FDA approval for new Tasigna indication; agency panel backs HRA Pharma's ulipristal
18 June 2010
Talecris teams up with Novartis to market rabies products; law firms investigate proposed buy by Grifols
16 June 2010
Novartis/Mitsubishi Tanabe's Gilenia remains on track for blockbuster sales in the multiple sclerosis drug market
16 June 2010
Human Genome Sciences sees little hope of FDA approval for hep C drug Zalbin in bi-monthly regimen
15 June 2010
FDA Advisory Committee unanimously backs Gilenia, putting Novartis ahead in race for oral MS drug
11 June 2010
ASCO highlights include cancer drug news from Pfizer, Roche, Sanofi, Merck KGaA, Novartis and Eisai
7 June 2010
UK’s NICE rejects Novartis’ Xolair for children suffering severe persistent allergic asthma, on cost grounds
2 June 2010
Novartis’ Onbrez Breezhaler significantly reduces COPD patient need for “relief” medication
19 May 2010
Sosei and Vectura get $7.5 million milestone each, as Novartis starts Ph III study with QVA149 and NVA237
10 May 2010
Alcon Independent Director Committee says Novartis’ offer still grossly inadequate, especially given Alcon’s strong earnings
29 April 2010
Neurologists eagerly await new oral treatment options for MS, such as EMD Serono's Movectro and Novartis' Gilenia
27 April 2010
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
